82.07 USD
▲+0.24+2.64%
2026-08-03
市值
$16.04B
市盈率
—
EPS
-3.75
股息率
—
52 周区间
42.09 – 93.42
成交量
1.69M
Beta
0.98
目标价
105.26
52W 低 42.0952W 高 93.42
价格走势
公司简介
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ...